Extended belantamab mafodotin dosing intervals were associated with maintained vision-related function in the phase 1 DREAMM-9 study.
|Poll|January 18, 2017
Patient Presents With Anterior Mediastinal Mass
Author(s)Cesar A. Moran, MD
A 43-year-old man presents with an anterior mediastinal mass. The mass is surgically resected and a biopsy is performed. What is your diagnosis?
Advertisement
Advertisement
Related to this article
The phase 3 NRG-GI003 trial showed no overall survival benefit with proton therapy over photon therapy in patients with advanced hepatocellular carcinoma.
In a secondary analysis of the DEPROMP trial, 94.8% of biopsy-naive men had no AEs immediately after multimodal MRI- and PSMA PET/CT–guided prostate biopsy.
C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.
Ethan B. Ludmir, MD, explains why advanced radiation techniques like protons fit nonoperative cholangiocarcinoma better than the preoperative setting.
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Ayal Aizer, MD, MHS, explains why fractionated SRS outperformed single-fraction SRS for surgical bed control in Alliance A071801.
Andy Liao, MD, discusses KRAS-targeted strategies, molecular profiling, multidisciplinary care, and FGFR2 inhibitor sequencing in cholangiocarcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Distal Extrahepatic Cholangiocarcinoma May Gain From Neoadjuvant Radiation
2
Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy
3
The Value of Testing in The Expanding EGFR Exon 20 Insertion Landscape
4
Sequencing CAR T Therapy and Bispecifics in Follicular and Mantle Cell Lymphoma
5